SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an
open- label#single center #non-randomized #Single Arm Exploratory Study . This clinical study
is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate
the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients
with advanced stage hepatocellular carcinoma.